GTx,Inc. (NASDAQ:GTXI) Files An 8-K Results of Operations and Financial Condition

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition.

Story continues below

On August14, 2017, GTx,Inc. issued its financial press release for the second quarter ended June30, 2017, a copy of which is furnished as Exhibit99.1 to this Current Report.

This release is furnished by GTx to Item 2.02 of Form8-K and is not to be considered “filed” under the Exchange Act, and shall not be incorporated by reference into any previous or future filing by the Registrant under the Securities Act or the Exchange Act.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number



Press Release issued by GTx,Inc. dated August14, 2017

GTX INC /DE/ Exhibit
EX-99.1 2 a17-20065_1ex99d1.htm EX-99.1 Exhibit 99.1   GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results   — Clinically significant reduction in incontinence episodes outlined in preliminary results from ongoing Phase 2 proof-of-concept clinical trial in stress urinary incontinence —   — Additional data from ongoing SUI clinical trial to be released in conjunction with podium presentation at International Continence Society meeting in September 2017 —   MEMPHIS,…
To view the full exhibit click here

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

An ad to help with our costs